Patents by Inventor Xavier Saelens
Xavier Saelens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240101647Abstract: Agents that bind to sarbecoviruses of multiple clades, neutralizing sarbecovirus infection, in particular neutralizing SARS-CoV-1 and SARS-CoV-2 infection. The agents bind to a unique epitope of the sarbecovirus ACE2-receptor binding domain (RBD) but do not inhibit binding of ACE2 with the RBD. Applications and uses of these agents are further disclosed.Type: ApplicationFiled: February 7, 2022Publication date: March 28, 2024Inventors: Xavier SAELENS, Dorien DE VLIEGER, Iebe ROSSEY, Sieglinde DE CAE, Koen SEDEYN, Loes VAN SCHIE, Hannah EECKHAUT, Daria FIJALKOWSKA, Catelijne STORTELERS, Bert SCHEPENS, Nico CALLEWAERT, Han REMAUT, Wim NERINCKX, Kenny ROOSE, Dirk REITER
-
Publication number: 20230227537Abstract: The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses.Type: ApplicationFiled: February 5, 2021Publication date: July 20, 2023Inventors: Bert SCHEPENS, Xavier SAELENS, Nico CALLEWAERT, Dorien DE VLIEGER, Loes VAN SCHIE, Wim NERINCKX, Kenny ROOSE, Wander VAN BREEDAM, Hannah EECKHAUT, Daria FIJALKOWSKA, Chiara LONIGRO, Sieglinde DE CAE, Bruno DOMBRECHT, Catelijne STORTELERS, Johan NEYTS, Leen DELANG, Suzanne KAPTEIN, Joana DUARTE DA ROCHA PEREIRA, Barney GRAHAM, Jason MCLELLAN, Daniel WRAPP, Han REMAUT
-
Patent number: 11248039Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: GrantFiled: September 10, 2019Date of Patent: February 15, 2022Assignees: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGEInventors: Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman
-
Publication number: 20210121522Abstract: The invention relates to the field of immuno-oncology. More in particular, it relates to applying the mixed-lineage kinase domain-like protein (MLKL) or variants thereof in immunotherapeutic treatment of cancer. The MLKL or variant thereof is inducing an adaptive immune response to cancer cells leading to treatment of primary tumors and preventing development of secondary tumor or tumor metastasis.Type: ApplicationFiled: September 7, 2018Publication date: April 29, 2021Inventors: Xavier Saelens, Lien Van Hoecke, Stefaan De Koker, Johan Grooten
-
Publication number: 20210106673Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: ApplicationFiled: October 23, 2020Publication date: April 15, 2021Inventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Publication number: 20210046176Abstract: The present disclosure relates to a cluster-based consensus approach for generating recombinant neuraminidase (NA) polypeptides. The disclosure further relates to influenza vaccine compositions comprising the recombinant NA polypeptides.Type: ApplicationFiled: March 27, 2019Publication date: February 18, 2021Applicants: SANOFI PASTEUR INC., VIB VZW, UNIVERSITEIT GENTInventors: Tod Strugnell, Eliud Oloo, Raymond Oomen, Thorsten Vogel, Xavier Saelens, Emma Job
-
Publication number: 20200102374Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: ApplicationFiled: September 10, 2019Publication date: April 2, 2020Inventors: Xavier SAELENS, Bert SCHEPENS, Iebe ROSSEY, Barney GRAHAM, Jason MCLELLAN, Morgan GILMAN
-
Patent number: 10501528Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: GrantFiled: June 20, 2016Date of Patent: December 10, 2019Assignees: V18 VZW, UNIVERSITEIT GENT, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES, TRUSTEES OF DARTMOUTH COLLEGEInventors: Xavier Saelens, Bert Schepens, Iebe Rossey, Barney Graham, Jason McLellan, Morgan Gilman
-
Publication number: 20190083605Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: ApplicationFiled: September 27, 2018Publication date: March 21, 2019Inventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Patent number: 10117926Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: GrantFiled: June 29, 2016Date of Patent: November 6, 2018Assignees: VIB VZW, UNIVERSITEIT GENTInventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Patent number: 10023629Abstract: The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenza virus infections, and to a pharmaceutical composition comprising the antibody.Type: GrantFiled: December 11, 2013Date of Patent: July 17, 2018Assignees: VIB VZW, UNIVERSITEIT GENT, VRIJE UNIVERSITEIT BRUSSELInventors: Xavier Saelens, Francisco Miguel Lopez Cardoso, Ann DePicker, Serge Muyldermans
-
Publication number: 20180179266Abstract: The present invention relates to immunoglobulin single variable domains (ISVDs) that are directed against respiratory syncytial virus (RSV). More specifically, it relates to ISVDs that bind to the prefusion form of the fusion (F) protein of RSV. The invention relates further to the use of these ISVDs for prevention and/or treatment of RSV infections, and to pharmaceutical compositions comprising these ISVDs.Type: ApplicationFiled: June 20, 2016Publication date: June 28, 2018Inventors: Xavier SAELENS, Bert SCHEPENS, Iebe ROSSEY, Barney GRAHAM, Jason MCLELLAN, Morgan GILMAN
-
Patent number: 9725522Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: GrantFiled: March 8, 2016Date of Patent: August 8, 2017Assignee: Ablynx N.V.Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Publication number: 20160376347Abstract: The present invention relates to an antibody that confers protection against influenza virus infection. More specifically, it relates to an anti-neuraminidase antibody, protecting against highly pathogenic H5N1 influenza strains. The invention relates further to the use of the antibody for prophylactic and/or therapeutic treatment of influenzavirusinfections, and to a pharmaceutical composition comprising the antibody.Type: ApplicationFiled: December 11, 2013Publication date: December 29, 2016Applicants: VIB VZW, Universiteit Gent, Vrije Universiteit BrusselInventors: Xavier Saelens, Francisco Miguel Lopez Cardoso, Ann DePicker, Serge Muyldermans
-
Publication number: 20160346379Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: ApplicationFiled: June 29, 2016Publication date: December 1, 2016Inventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Patent number: 9505849Abstract: The present invention relates to an antibody construct comprising a first human binding domain specific for the extracellular part of the influenza envelope protein M2 (M2e) and a second domain specific for CD3. Moreover, the invention provides a nucleic acid molecule encoding the antibody construct, a vector comprising said nucleic acid molecule and a host cell transformed or transfected with said nucleic acid molecule or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a pharmaceutical composition comprising said antibody construct, a medical use/method of treatment relating to said antibody construct, and a kit comprising said antibody construct.Type: GrantFiled: March 17, 2014Date of Patent: November 29, 2016Assignees: AMGEN RESEARCH (MUNICH) GMBH, VIB VZW, Universiteit GentInventors: Peter Kufer, Tobias Raum, Markus Muenz, Jochen Pendzialek, Walter Fiers, Xavier Saelens, Kenny Roose
-
Publication number: 20160280799Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: ApplicationFiled: March 8, 2016Publication date: September 29, 2016Applicant: Ablynx NV.Inventors: MARIE-PAULE LUCIENNE ARMANDA BOUCHE, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Patent number: 9409973Abstract: Described is a vaccine against Respiratory Syncytial Virus (RSV). More specifically, described is a recombinant subunit vaccine comprising the ectodomain of the RSV-encoded Small Hydrophobic (SH) protein. The ectodomain of SH is referred to as SHe. The ectodomain is typically presented as an oligomer, or a pentamer. Further described are antibodies, raised against the ectodomain or specific for the ectodomain, and their use for protecting a subject against RSV infection and/or for treatment of an infected subject.Type: GrantFiled: November 15, 2011Date of Patent: August 9, 2016Assignees: VIB VZW, Universiteit GentInventors: Xavier Saelens, Bert Schepens, Walter Fiers
-
Patent number: 9320792Abstract: In one aspect, the invention relates to a method suitable for administering protein therapeutic molecules orally, sublingually, topically, intravenously, subcutaneously, nasally, vaginally, rectally or by inhalation so as to avoid inactivation, by using VHH polypeptides derived from Camelidae antibodies. The invention further relates to the said therapeutic molecules. The invention further a method for delivering therapeutic molecules to the interior of cells. The invention further relates to anti-IgE therapeutic molecules. In one aspect, the present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.Type: GrantFiled: February 7, 2013Date of Patent: April 26, 2016Assignee: Ablynx N.V.Inventors: Marie-Paule Lucienne Armanda Bouche, Peter Vanlandschoot, Erwin Sablon, Erik Depla, Stefan De Buck, Xavier Saelens, Bert Schepens, Karen Silence, Mark Vaeck, Paul M. P. Van Bergen En Henegouwen, Hans De Haard
-
Publication number: 20160039948Abstract: The present invention relates to an antibody construct comprising a first human binding domain specific for the extracellular part of the influenza envelope protein M2 (M2e) and a second domain specific for CD3. Moreover, the invention provides a nucleic acid molecule encoding the antibody construct, a vector comprising said nucleic acid molecule and a host cell transformed or transfected with said nucleic acid molecule or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a pharmaceutical composition comprising said antibody construct, a medical use/method of treatment relating to said antibody construct, and a kit comprising said antibody construct.Type: ApplicationFiled: March 17, 2014Publication date: February 11, 2016Applicant: AMGEN RESEARCH (MUNICH) GMBHInventors: Peter Kufer, Tobias Raum, Markus Muenz, Jochen Pendzialek, Walter Fiers, Xavier Saelens, Kenny Roose